TapewireFind a company

person · Reporting owner

Murphy Polly A.

Disclosed activity across 2 companies

Tapewire entity
35902
SEC CIK
0001829248

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Atea Pharmaceuticals, Inc.AVIR · Entity 5580DirectorJune 18, 2026June 23, 2026
Celcuity Inc.CELC · Entity 3991DirectorJune 10, 2026June 12, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Atea Pharmaceuticals, Inc.

Report date June 18, 2026 · Filed June 23, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect121,745 Reported balance After 2026-06-18 transaction · row 1
1 source row

Row 1 · 2026-06-18 · Exercise / conversion · Acquired 29,600 · Balance 121,745

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2026-06-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-06-18 · Exercise / conversion · Disposed 29,600 · Balance 0

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2: The RSUs vested in full on June 18, 2026.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect26,700 Reported balance After 2026-06-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-06-18 · Grant · Acquired 26,700 · Balance 26,700

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F3: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.36 · Expires 2036-06-17Direct37,700 Reported balance After 2026-06-18 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2026-06-18 · Grant · Acquired 37,700 · Balance 37,700

F4: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2: The RSUs vested in full on June 18, 2026.

F3: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

F4: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date.

Celcuity Inc.

Report date June 10, 2026 · Filed June 12, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.69 · Expires 2035-05-19Direct0 Reported balance After 2026-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-06-10 · Gift · Disposed 14,048 · Balance 0

F1: 100% vested.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.69 · Expires 2035-05-19IndirectBy Trust14,048 Reported balance After 2026-06-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-06-10 · Gift · Acquired 14,048 · Balance 14,048

F1: 100% vested.

F2: The reporting person and her spouse are the trustees and beneficiaries. The reporting person continues to beneficially own these securities held by the trust.

Filing footnotes · ownership attribution and instrument terms

F1: 100% vested.

F2: The reporting person and her spouse are the trustees and beneficiaries. The reporting person continues to beneficially own these securities held by the trust.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 18, 2026 Filed Jun 23, 2026 21:00 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 GrantStock Option (Right to Buy) · Derivative 37,700 $0.00 Strike: $4.36 $0.00
Disclosure

SEC source: 0001193125-26-279718 · ownership.xml · derivative · entry 4

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,700

Underlying: Common Stock · 37,700 shares

Expires 2036-06-17

F4 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date.

Read SEC document
June 18, 2026 Filed Jun 23, 2026 21:00 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 GrantRestricted Stock Units · Derivative 26,700 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-279718 · ownership.xml · derivative · entry 3

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,700

Underlying: Common Stock · 26,700 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F3 · derivative.exercise_date: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

F3 · derivative.expiration_date: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

Read SEC document
June 18, 2026 Filed Jun 23, 2026 21:00 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 Exercise / conversionRestricted Stock Units · Derivative 29,600 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-279718 · ownership.xml · derivative · entry 2

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 29,600 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: The RSUs vested in full on June 18, 2026.

F2 · derivative.expiration_date: The RSUs vested in full on June 18, 2026.

Read SEC document
June 18, 2026 Filed Jun 23, 2026 21:00 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 Exercise / conversionCommon Stock 29,600 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-279718 · ownership.xml · nonDerivative · entry 1

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,745

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
June 10, 2026 Filed Jun 12, 2026 20:18 UTC Celcuity Inc. CELC · Entity 3991 GiftStock Option (right to buy) · Derivative 14,048 $0.00 Strike: $10.69 $0.00
Disclosure

SEC source: 0001829248-26-000004 · form4-06122026_080606.xml · derivative · entry 2

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 14,048

Underlying: Common Stock · 14,048 shares

Expires 2035-05-19

F1 · derivative.exercise_date: 100% vested.

F2 · ownership.nature: The reporting person and her spouse are the trustees and beneficiaries. The reporting person continues to beneficially own these securities held by the trust.

Read SEC document
June 10, 2026 Filed Jun 12, 2026 20:18 UTC Celcuity Inc. CELC · Entity 3991 GiftStock Option (right to buy) · Derivative 14,048 $0.00 Strike: $10.69 $0.00
Disclosure

SEC source: 0001829248-26-000004 · form4-06122026_080606.xml · derivative · entry 1

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,048 shares

Expires 2035-05-19

F1 · derivative.exercise_date: 100% vested.

Read SEC document
June 05, 2026 Filed Jun 9, 2026 22:25 UTC Celcuity Inc. CELC · Entity 3991 GrantCommon Stock 1,530 $0.00 $0.00
Disclosure

SEC source: 0001829248-26-000002 · form4-06092026_100617.xml · nonDerivative · entry 1

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,530

F1 · shares: Represents restricted stock units that will vest upon the earlier of (i) the 2027 annual meeting of stockholders of Celcuity Inc. or (ii) April 30, 2027.

Read SEC document
May 18, 2026 Filed May 21, 2026 22:30 UTC Amendment Atea Pharmaceuticals, Inc. AVIR · Entity 5580 PurchaseCommon Stock 6,100 $4.17 $25,446.15
Disclosure

SEC source: 0001193125-26-235039 · ownership.xml · nonDerivative · entry 1

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,145

F1 · date: This Form 4/A has been filed solely to correct the date of the transaction reported in Column 2 of Table I of the Reporting Person's Form 4 filed on May 20, 2026, which was inadvertently noted as "May 18, 2025" instead of "May 18, 2026."

F2 · price: The price reported in Column 4 is a weighted average price. The securities were purchased in multiple transactions at prices ranging from $4.14 to $4.19 per share of common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Read SEC document
June 20, 2025 Filed Jun 24, 2025 22:05 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 Exercise / conversionRestricted Stock Units · Derivative 29,600 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-089607 · ownership.xml · derivative · entry 4

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 29,600 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: The restricted stock units were fully vested as of June 20, 2025

F4 · derivative.expiration_date: The restricted stock units were fully vested as of June 20, 2025

Read SEC document
June 20, 2025 Filed Jun 24, 2025 22:05 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 GrantStock Option (Right to Buy) · Derivative 41,200 $0.00 Strike: $3.25 $0.00
Disclosure

SEC source: 0000950170-25-089607 · ownership.xml · derivative · entry 3

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,200

Underlying: Common Stock · 41,200 shares

Expires 2035-06-19

F3 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 20, 2025, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date.

Read SEC document
June 20, 2025 Filed Jun 24, 2025 22:05 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 GrantRestricted Stock Units · Derivative 29,600 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-089607 · ownership.xml · derivative · entry 2

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,600

Underlying: Common Stock · 29,600 shares

Expires not disclosed

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

F2 · derivative.expiration_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

Read SEC document
June 20, 2025 Filed Jun 24, 2025 22:05 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 Exercise / conversionCommon Stock 29,600 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-089607 · ownership.xml · nonDerivative · entry 1

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,045

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
May 28, 2025 Filed May 29, 2025 20:21 UTC Celcuity Inc. CELC · Entity 3991 GiftStock Option (right to buy) · Derivative 8,153 $0.00 Strike: $14.83 $0.00
Disclosure

SEC source: 0001415889-25-014864 · form4-05292025_080514.xml · derivative · entry 6

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 8,153

Underlying: Common Stock · 8,153 shares

Expires 2034-06-04

F1 · derivative.exercise_date: 100% vested.

F2 · ownership.nature: The Reporting Person and his spouse are the trustees and beneficiaries. The Reporting Person continues to beneficially own these securities held by the trust.

Read SEC document
May 28, 2025 Filed May 29, 2025 20:21 UTC Celcuity Inc. CELC · Entity 3991 GiftStock Option (right to buy) · Derivative 8,153 $0.00 Strike: $14.83 $0.00
Disclosure

SEC source: 0001415889-25-014864 · form4-05292025_080514.xml · derivative · entry 5

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,153 shares

Expires 2034-06-04

F1 · derivative.exercise_date: 100% vested.

Read SEC document
May 19, 2025 Filed May 21, 2025 20:42 UTC Celcuity Inc. CELC · Entity 3991 GrantStock Option (right to buy) · Derivative 14,048 $0.00 Strike: $10.69 $0.00
Disclosure

SEC source: 0001415889-25-013945 · form4-05212025_080522.xml · derivative · entry 1

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,048

Underlying: Common Stock · 14,048 shares

Expires 2035-05-19

F1 · derivative.exercise_date: This Option will vest and become exercisable on April 30, 2026, or if earlier, the date of the Company's 2026 Annual Meeting of Stockholders.

Read SEC document
May 18, 2025 Filed May 20, 2026 20:15 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 PurchaseCommon Stock 6,100 $4.17 $25,446.15
Disclosure

SEC source: 0001193125-26-232612 · ownership.xml · nonDerivative · entry 1

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,145

F1 · price: The price reported in Column 4 is a weighted average price. The securities were purchased in multiple transactions at prices ranging from $4.14 to $4.19 per share of common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Read SEC document
June 24, 2024 Filed May 29, 2025 20:21 UTC Celcuity Inc. CELC · Entity 3991 GiftStock Option (right to buy) · Derivative 11,645 $0.00 Strike: $9.58 $0.00
Disclosure

SEC source: 0001415889-25-014864 · form4-05292025_080514.xml · derivative · entry 4

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 11,645

Underlying: Common Stock · 11,645 shares

Expires 2033-05-15

F1 · derivative.exercise_date: 100% vested.

F2 · ownership.nature: The Reporting Person and his spouse are the trustees and beneficiaries. The Reporting Person continues to beneficially own these securities held by the trust.

Read SEC document
June 24, 2024 Filed May 29, 2025 20:21 UTC Celcuity Inc. CELC · Entity 3991 GiftStock Option (right to buy) · Derivative 11,645 $0.00 Strike: $9.58 $0.00
Disclosure

SEC source: 0001415889-25-014864 · form4-05292025_080514.xml · derivative · entry 3

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,645 shares

Expires 2033-05-15

F1 · derivative.exercise_date: 100% vested.

Read SEC document
June 24, 2024 Filed May 29, 2025 20:21 UTC Celcuity Inc. CELC · Entity 3991 GiftStock Option (right to buy) · Derivative 16,300 $0.00 Strike: $8.31 $0.00
Disclosure

SEC source: 0001415889-25-014864 · form4-05292025_080514.xml · derivative · entry 2

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 16,300

Underlying: Common Stock · 16,300 shares

Expires 2032-09-12

F1 · derivative.exercise_date: 100% vested.

F2 · ownership.nature: The Reporting Person and his spouse are the trustees and beneficiaries. The Reporting Person continues to beneficially own these securities held by the trust.

Read SEC document
June 24, 2024 Filed May 29, 2025 20:21 UTC Celcuity Inc. CELC · Entity 3991 GiftStock Option (right to buy) · Derivative 16,300 $0.00 Strike: $8.31 $0.00
Disclosure

SEC source: 0001415889-25-014864 · form4-05292025_080514.xml · derivative · entry 1

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,300 shares

Expires 2032-09-12

F1 · derivative.exercise_date: 100% vested.

Read SEC document
June 21, 2024 Filed Jun 21, 2024 21:54 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 GrantStock Option (Right to Buy) · Derivative 41,200 $0.00 Strike: $3.44 $0.00
Disclosure

SEC source: 0000950170-24-076363 · ownership.xml · derivative · entry 2

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,200

Underlying: Common Stock · 41,200 shares

Expires 2034-06-20

F3 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 21, 2024, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date.

Read SEC document
June 21, 2024 Filed Jun 21, 2024 21:54 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 GrantRestricted Stock Units · Derivative 29,600 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-076363 · ownership.xml · derivative · entry 1

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,600

Underlying: Common Stock · 29,600 shares

Expires not disclosed

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

F2 · derivative.expiration_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

Read SEC document
June 16, 2024 Filed Jun 18, 2024 21:00 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 Exercise / conversionRestricted Stock Units · Derivative 33,150 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-074989 · ownership.xml · derivative · entry 2

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 33,150 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis.

F2 · derivative.exercise_date: The restricted stock unites are fully vested.

F3 · derivative.expiration_date: The restricted stock units do not have an expiration date.

Read SEC document
June 16, 2024 Filed Jun 18, 2024 21:00 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 Exercise / conversionCommon Stock 33,150 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-074989 · ownership.xml · nonDerivative · entry 1

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,445

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units convert into common stock on a one-for-one basis.

Read SEC document
June 04, 2024 Filed Jun 6, 2024 20:16 UTC Celcuity Inc. CELC · Entity 3991 GrantStock Option (right to buy) · Derivative 8,153 $0.00 Strike: $14.83 $0.00
Disclosure

SEC source: 0001062993-24-012032 · form4.xml · derivative · entry 5

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,153

Underlying: Common Stock · 8,153 shares

Expires 2034-06-04

F3 · derivative.exercise_date: This Option will vest and become exercisable on April 30, 2025, or if earlier, the date of the Company's 2025 Annual Meeting of Stockholders.

Read SEC document
June 16, 2023 Filed Jun 21, 2023 20:05 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 GrantStock Option (Right to Buy) · Derivative 46,750 $0.00 Strike: $4.12 $0.00
Disclosure

SEC source: 0000899243-23-016129 · doc4.xml · derivative · entry 2

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,750

Underlying: Common Stock · 46,750 shares

Expires 2033-06-15

F3 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 16, 2023, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date.

Read SEC document
June 16, 2023 Filed Jun 21, 2023 20:05 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 GrantRestricted Stock Units · Derivative 33,150 $0.00 $0.00
Disclosure

SEC source: 0000899243-23-016129 · doc4.xml · derivative · entry 1

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,150

Underlying: Common Stock · 33,150 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

F2 · derivative.expiration_date: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

Read SEC document
May 15, 2023 Filed May 17, 2023 20:26 UTC Celcuity Inc. CELC · Entity 3991 GrantStock Option (right to buy) · Derivative 11,645 $0.00 Strike: $9.58 $0.00
Disclosure

SEC source: 0001062993-23-011389 · form4.xml · derivative · entry 4

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,645

Underlying: Common Stock · 11,645 shares

Expires 2033-05-15

F3 · derivative.exercise_date: This Option will vest and become exercisable on April 30, 2024, or if earlier, the date of the Company's 2024 Annual Meeting of Stockholders.

Read SEC document
November 22, 2022 Filed Nov 23, 2022 21:10 UTC Celcuity Inc. CELC · Entity 3991 PurchaseCommon Stock 5,000 $9.68 $48,383.00
Disclosure

SEC source: 0001062993-22-022722 · form4.xml · nonDerivative · entry 1

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.6500 to $9.7000 inclusive. The reporting person undertakes to provide Celcuity Inc., any security holder of Celcuity Inc., or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Read SEC document
September 12, 2022 Filed Sep 14, 2022 20:06 UTC Celcuity Inc. CELC · Entity 3991 GrantStock Option (right to buy) · Derivative 16,300 $0.00 Strike: $8.31 $0.00
Disclosure

SEC source: 0001437749-22-022425 · rdgdoc.xml · derivative · entry 2

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,300

Underlying: Common Stock · 16,300 shares

Expires 2032-09-12

F2 · derivative.exercise_date: This Option will vest and become exercisable on April 30, 2023, or if earlier, the date of the Company's 2023 Annual Meeting of Stockholders.

Read SEC document
September 12, 2022 Filed Sep 14, 2022 20:06 UTC Celcuity Inc. CELC · Entity 3991 GrantStock Option (right to buy) · Derivative 10,000 $0.00 Strike: $8.31 $0.00
Disclosure

SEC source: 0001437749-22-022425 · rdgdoc.xml · derivative · entry 1

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2032-09-12

F1 · derivative.exercise_date: 2,500 shares vest on each of 9/12/23, 9/12/24, 9/12/25 and 9/12/26.

Read SEC document
June 17, 2022 Filed Jun 21, 2022 23:47 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 GrantStock Option (Right to Buy) · Derivative 61,264 $0.00 Strike: $6.50 $0.00
Disclosure

SEC source: 0000899243-22-023501 · doc4.xml · derivative · entry 1

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,264

Underlying: Common Stock · 61,264 shares

Expires 2032-06-16

F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) equal monthly installments following June 17, 2022, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date.

Read SEC document
December 20, 2021 Filed Dec 22, 2021 02:41 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 PurchaseCommon Stock 12,000 $8.57 $102,795.60
Disclosure

SEC source: 0000899243-21-049313 · doc4.xml · nonDerivative · entry 1

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,295

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.45 to $8.66, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Read SEC document
June 18, 2021 Filed Jun 21, 2021 21:30 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 GrantStock Option (Right to Buy) · Derivative 34,025 $0.00 Strike: $23.39 $0.00
Disclosure

SEC source: 0000899243-21-025037 · doc4.xml · derivative · entry 1

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,025

Underlying: Common Stock · 34,025 shares

Expires 2031-06-17

F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) equal monthly installments following June 18, 2021, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date.

Read SEC document
November 03, 2020 Filed Nov 4, 2020 01:09 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 ConversionSeries D-1 Convertible Preferred Stock · Derivative 4,173 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-030332 · doc4.xml · derivative · entry 3

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by the Marc & Polly Murphy Revocable Family Trust dated March 13, 2002

Disclosed balance after: 0

Underlying: Common Stock · 4,173 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock.

F1 · price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock.

F1 · derivative.exercise_date: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock.

F1 · derivative.expiration_date: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock.

Read SEC document
November 03, 2020 Filed Nov 4, 2020 01:09 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 ConversionSeries D Convertible Preferred Stock · Derivative 7,122 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-030332 · doc4.xml · derivative · entry 2

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by the Marc & Polly Murphy Revocable Family Trust dated March 13, 2002

Disclosed balance after: 0

Underlying: Common Stock · 7,122 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock.

F1 · price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock.

F1 · derivative.exercise_date: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock.

F1 · derivative.expiration_date: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock.

Read SEC document
November 03, 2020 Filed Nov 4, 2020 01:09 UTC Atea Pharmaceuticals, Inc. AVIR · Entity 5580 ConversionCommon Stock 11,295 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-030332 · doc4.xml · nonDerivative · entry 1

Murphy Polly A. · CIK 0001829248 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by the Marc & Polly Murphy Revocable Family Trust dated March 13, 2002

Disclosed balance after: 11,295

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.